Drugs / BCD-217
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03913923 | Jul 2019 → Jul 2023 | metastatic melanoma | Biocad | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-217 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03913923 ↗ |
| Modality | Monoclonal antibody | “fixed dose combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies” NCT03913923 ↗ |
| Route | Intravenous | “given Q3W as IV infusion for first 4 blinded infusions” NCT03913923 ↗ |